Verrica Pharmaceuticals (VRCA) announced that its development partner, Torii Pharmaceutical has received approval from the Japanese Ministry of Health, Labour and Welfare, MHLW, for YCANTH, TO-208, for the treatment of Molluscum Contagiosum. Torii became a wholly-owned subsidiary of Shionogi & Co, on September 1, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals’ Earnings Call Highlights Growth and Strategic Moves
- Verrica Pharmaceuticals: Promising Sales Growth Amid Financial Stability Concerns
- Verrica Pharmaceuticals Sees Revenue Surge in Q2 2025
- Promising Sales Growth and Strategic Initiatives Drive Buy Rating for Verrica Pharmaceuticals
- Verrica Pharmaceuticals Regains Nasdaq Compliance